Project Grant R01HL185298
Award Date 8/19/26
Completion Date 4/30/31
Dollars Obligated $599K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Iowa City, IA 52242, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The University of Iowa $660,875 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on TGF-β signaling in the pathogenesis of lymphangioleiomyomatosis (LAM). The recipient will engineer novel multicellular three-dimensional organoid and lung-on-chip models to test the effects of TGF-β signaling on the growth of LAM nodules and to identify mechanisms that drive nodule growth and alveolar...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $1,151,498 on March 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on lung epithelial development and regeneration. The research aims to restore epithelial integrity and prevent end-stage lung diseases such as idiopathic pulmonary fibrosis by understanding how the lung epithelium develops in embryos and regenerates following injury....
- The National Heart, Lung, and Blood Institute awarded The Washington University $1.902 million on June 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define and correct immune-epithelial pathways underlying chronic muco-obstructive lung disease triggered by viral infection, allergen, smoke, or pollution exposure. The research identifies and characterizes a distinct subset of basal epithelial stem cells (basal-ESCs) that drive muco-obstructive disease phenotypes...
- The National Heart, Lung, and Blood Institute awarded the University of Alabama at Birmingham $678,379 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to study the cellular biology and function of pulmonary ionocytes. The research investigates pulmonary ionocytes, rare epithelial cells in surface airway epithelium and submucosal glands that highly express the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ionocytes regulate airway surface...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $873,801 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate epithelial reprogramming mechanisms that distinguish normal regenerative repair from pathologic fibrotic remodeling in chronic lung diseases, particularly idiopathic pulmonary fibrosis. The research examines how airway and alveolar epithelial stem and progenitor cells progress through intermediate...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded National Jewish Health $249,000 on July 24, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate rare airway cell function in post-viral chronic inflammation. The research examines the role of microfold (M) cells in the post-influenza lung, particularly their contribution to secondary bacterial infection susceptibility and host protection. Using single-nucleus transcriptomic and...
- The National Heart, Lung, and Blood Institute awarded The Trustees Of The University Of Pennsylvania $1,624,110 on June 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms of lung repair and regeneration following acute injury. The project examines dysplastic versus euplastic repair pathways in lung tissue. The research addresses how basal stem cells migrate into the alveolar niche after injury, displacing AT2 progenitor cells and creating an...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $750,330 on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate MUC5AC structure, function, interactome, and its role in airway obstruction. The research addresses the molecular mechanisms by which MUC5AC, an airway mucin, contributes to chronic obstructive pulmonary disease and asthma pathogenesis. The project will define MUC5AC's unique macromolecular...
- The National Heart, Lung, and Blood Institute awarded $777,498 to the University of North Carolina at Chapel Hill on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on multiscale integration of mucin secretion and ion transport rates in asthmatic mucus plug formation and persistence. The research tests the applicability of a biophysical paradigm called the "two-gel" paradigm to asthma pathogenesis, examining whether asthma mucus...
- Federal Grant Award Summary The University of Iowa received a $422,075 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 15, 2025, with a completion date of July 31, 2027. The grant funds development of an electromagnetic-actuated dynamic cell culture system designated "MagniWell-12," designed to advance research on airway epithelial cells by simulating physiological stretch-relax...